Elanco Animal Health (ELAN)
Develops medicines, vaccines, and feed products for pets and farm animals.
Something off on this page? Send us feedback.
Develops medicines, vaccines, parasiticides, and feed products for pets and farm animals across one reportable segment. Pet Health and Farm Animal contribute roughly equal revenue, sales are split about evenly between U.S. and international markets, and product approvals, safety oversight, livestock-use rules, and acquisition debt shape the business.
Develops medicines, vaccines, parasiticides, and feed products for pets and farm animals under roughly 200 brands. Pet Health includes Advantage, Seresto, Credelio, Zenrelia, and Credelio Quattro, while Farm Animal includes Rumensin, Maxiban/Monteban, and Bovaer. Both categories sit inside one reportable segment.
Sales are split roughly half between the United States and international markets. The portfolio spans canine and feline care alongside cattle, poultry, and swine health, with recent launches extending pet therapeutics, parasite control, and livestock sustainability products.
Product approvals, safety oversight, and livestock-use rules shape market access. Seresto remains registered with enhanced EPA reporting and label conditions, while the Bayer combination left acquisition debt addressed through portfolio sales, repayment, and refinancing.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 6, 2026 | KeyBanc | Reiterate | Rating: —Target: $29 | Target: $30 |
| Jul 22, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $23 | Target: $26 |
| May 15, 2026 | Morgan Stanley | Target | Target: $22 | Target: $23 |
| Feb 25, 2026 | Keybanc | Reiterate | Rating: —Target: $27 | Target: $29 |
| Feb 24, 2026 | Leerink Partners | Reiterate | Rating: —Target: $18 | Target: $30 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $530.0M · Total debt $3.92B · Total assets $13.56B · Shareholders' equity $6.59B
- Revenue
- $1.37B
- Operating income
- $109.0M
- Net income
- $54.0M
No dividends on record.
| Institutions | 114.19% | 570.51M shares | |
|---|---|---|---|
| 534 holders · as of Jun 30, 2026 | |||
| Insiders | 3.44% | 17.21M shares | |
| 27 holders · as of Aug 21, 2026 | |||
| Adds to | 117.63% | ||
499.62M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 117.63%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Dodge & CoxInstitution | 13.49% | 67.40M | as of Jun 30, 2026 |
FMR LLCInstitution | 11.40% | 56.95M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 9.78% | 48.85M | as of Jun 30, 2026 |
Primecap Management Co/CA/Institution | 9.10% | 45.45M | as of Jun 30, 2026 |
Aristotle Capital Management, LLCInstitution | 5.85% | 29.21M | filed Feb 14, 2022 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 20, 2026 | Lawrence Erik Kurzius | director | +40,000 | $23.40 |
| Aug 18, 2026 | Shiv O'Neill | officer: GC AND CORP SEC | +3,998 | $23.58 |
| Aug 12, 2026 | Michael J. Harrington | director | +5,000 | $21.82 |
| Aug 7, 2026 | Paul Herendeen | director | +10,000 | $23.69 |
| Aug 7, 2026 | Robert M. VanHimbergen | officer: EVP and CFO | +4,200 | $23.08 |
- Zoetis
Broad global rival across pet and livestock animal health
- Merck
Large animal-health rival in parasiticides and livestock products
- Phibro Animal Health
Focused rival in medicated feed additives and livestock vaccines
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Elanco Animal Health | $22.79 | +1.60% | $11.20B | — | 19.2 | 2.2 | +10.2% |
| Zoetis | $71.61 | +0.39% | $29.90B | 11.8 | 11.5 | 3.1 | +0.3% |
| Merck | $151.34 | +1.23% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Phibro Animal Health | $34.98 | +0.88% | $1.41B | 14.2 | 10.0 | 0.9 | +4.8% |
| Median | 14.2 | 11.5 | 3.1 | +4.8% |